Shanghai, China, 28 January 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. ("ImmuneCare"), has filed the invention patent application for IMC-015, a differentiated bispecific antibody, and that the program has entered CMC and non-clinical development.

Obesity is a global health problem defined by a body-mass index (BMI) ≥ 30 kg/m². WHO data show that the worldwide obese population has surpassed 1.5 billion; in China the prevalence has risen almost ten-fold in the past three decades. Latest 2025 figures indicate that hundreds of millions of Chinese are now obese. Beyond higher body-weight, obesity is a major driver of type 2 diabetes, cardiovascular disease and mental-health disorders, severely reducing quality of life. Although GLP-1 receptor agonists induce marked weight loss, studies demonstrate that part of the reduction comes from skeletal-muscle loss, which can impair strength, basal metabolic rate and overall health—especially in older adults. Maintaining muscle mass during slimming is therefore a key unmet need and a central goal for next-generation obesity therapeutics.

About IMC-015
IMC-015 is an anti-pro/latent GDF8×ActRIIs bispecific antibody discovered by ImmuneCare. It combines high-affinity binding to latent (pro) GDF8 with a re-balanced ActRIIA/ActRIIB engagement profile designed to enhance muscle specificity and limit off-tissue activity. In vitro, IMC-015 displays ~2.5-fold higher affinity for human latent GDF8 (KD 8.12×10⁻¹⁰ M) than published clinical-stage molecules and shows markedly superior pathway-blocking potency in cell-based assays. Relative to benchmark molecules, the antibody weakens ActRIIB binding while preserving ActRIIA interaction, an approach expected to improve safety margins.

In a human-GDF8 diet-induced-obese (DIO) mouse model, animals receiving IMC-015 plus semaglutide exhibited:

• +6.89 % and +6.81 % higher lean-body mass vs semaglutide alone on days 21 and 28, respectively

• Further reduction in fat mass

• Superior fat-loss & muscle-gain efficacy versus comparator agents at equimolar doses (p < 0.05)

These findings validate IMC-015's potential to deliver additive body-composition benefits when combined with GLP-1 therapy.

Dr. Wenzhi Tian, Founder, Chairman, CEO & CSO of ImmuneOnco and Founder of ImmuneCare, commented:
"IMC-015's molecular design offers three key differentiators: first, an improved safety profile achieved by re-balancing receptor affinities; second, highly specific targeting of the muscle growth-inhibitory pathway, minimizing off-target effects; and third, synergistic efficacy—pre-clinical data show 'fat-loss & muscle-gain' benefits that address the muscle-wasting shortfall of current weight-management drugs. We look forward to IMC-015 becoming a preferred add-on to GLP-1 regimens, especially for patients seeking sustained, health-oriented weight control."

Forward-Looking Statements
This announcement contains forward-looking statements regarding IMC-015's development timeline and therapeutic potential. Actual results may differ materially due to risks and uncertainties inherent in drug R&D. ImmuneOnco assumes no obligation to update forward-looking information.